BIOATLA INC. DL-,0001

BioAtla will implement a 50-for-1 stock consolidation effective April 6, 2026, to increase the trading price per share and meet Nasdaq’s $1.00 minimum bid price requirement. Shareholders approved the measure at a special meeting; fractional shares will be paid in cash. The consolidation will proportionally reduce the number of shares available under stock option and employee plans, and option exercise prices and share quantities will be adjusted accordingly. » More on de.investing.com

BioAtla announced that trading of its shares on the Nasdaq Capital Market will be suspended as of Monday after a Nasdaq hearing panel found noncompliance with the $1.00 minimum bid price requirement and that shareholders’ equity fell below the $2.5 million threshold. The company requested an immediate review and a stay of the suspension but initially received no approval; BioAtla intends to appeal the delisting decision. If the suspension takes effect, BioAtla plans to have its common shares quoted on the OTCID market and is pursuing financing measures, including a $40 million special-purpose vehicle transaction with an initial $5 million payment, as well as a planned 1-for-50 reverse stock split. » More on de.investing.com

BioAtla announced a merger with a 100% subsidiary that provides for a 1:50 reverse split after NASDAQ changed its interpretation of voting rules. Earlier, the issuance of a voting preferred share had been intended to ease approval; this was subsequently withdrawn. Management does not want to carry out the split while the company remains listed on NASDAQ. In addition, BioAtla confirms a $5m investment from Alliance International in Inversagen AI and an SPV financing of $40m to fund the phase‑3 trial of Ozuriftamab Vedotin, with $5m to be paid immediately and $35m expected in Q1 2026; the company remains under watch due to rising losses and limited cash. » More on de.investing.com